Surrozen, Inc. $SRZN Stock: Regents of The University of California Decreases Stake

Regents of The University of California decreased its position in Surrozen, Inc. (NASDAQ:SRZN) by 38.5% in the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 133,207 shares of the company’s stock after selling 83,333 shares during the quarter. Surrozen makes up 0.1% of Regents of The University of California’s portfolio, making the stock its 10th biggest position. Regents of The University of California’s holdings in Surrozen were worth $4,287,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also added to or reduced their stakes in the company. Perceptive Advisors LLC bought a new stake in shares of Surrozen during the 1st quarter valued at $6,682,000. Renaissance Technologies LLC grew its position in shares of Surrozen by 117.1% in the 1st quarter. Renaissance Technologies LLC now owns 49,126 shares of the company’s stock worth $1,431,000 after buying an additional 26,500 shares during the period. Bank of New York Mellon Corp bought a new position in shares of Surrozen in the 2nd quarter worth about $399,000. Finally, ADAR1 Capital Management LLC bought a new position in shares of Surrozen in the 1st quarter worth about $350,000. Hedge funds and other institutional investors own 66.57% of the company’s stock.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on SRZN shares. Zacks Research raised shares of Surrozen from a “strong sell” rating to a “hold” rating in a research report on Tuesday, July 28th. William Blair assumed coverage on shares of Surrozen in a report on Thursday, August 20th. They issued an “outperform” rating and a $51.00 price objective on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Surrozen in a report on Thursday, October 15th. Finally, HC Wainwright reaffirmed a “buy” rating and set a $54.00 target price (up from $44.00) on shares of Surrozen in a research note on Friday, September 25th. One equities research analyst has rated the stock with a Strong Buy rating, four have given a Buy rating, one has given a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, Surrozen has an average rating of “Moderate Buy” and a consensus target price of $48.33.

Surrozen Trading Up 8.2%

Shares of NASDAQ:SRZN opened at $29.53 on Wednesday. The stock has a fifty day simple moving average of $23.96 and a two-hundred day simple moving average of $24.81. The stock has a market capitalization of $342.84 million, a price-to-earnings ratio of -0.73 and a beta of 0.47. Surrozen, Inc. has a 12-month low of $11.39 and a 12-month high of $37.83.

Surrozen (NASDAQ:SRZN) last released its earnings results on Thursday, August 6th. The company reported ($0.41) EPS for the quarter, topping the consensus estimate of ($1.29) by $0.88. The company had revenue of $5.00 million during the quarter, compared to the consensus estimate of $0.47 million. As a group, equities research analysts predict that Surrozen, Inc. will post -1.01 EPS for the current year.

Surrozen Profile

Surrozen, Inc is a clinical-stage biotechnology company focused on developing regenerative medicines that selectively activate the Wnt signaling pathway. Wnt signaling plays an important role in tissue development, repair and regeneration, and Surrozen is working to harness the pathway while limiting the potential safety risks associated with broad or uncontrolled activation.

The company uses its SWEETS (Surrozen Wnt Engineered Efficacious Therapeutics) platform to discover and engineer antibody-based medicines designed to modulate Wnt signaling in specific tissues.